Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where W. Rayford is active.

Publication


Featured researches published by W. Rayford.


The Journal of Urology | 1999

Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery.

McClellan M. Walther; Peter L. Choyke; Gladys M. Glenn; J. Chris Lyne; W. Rayford; David Venzon; W. Marston Linehan

PURPOSE Patients with hereditary forms of renal cancer are at risk for new tumors and metastases. Renal parenchymal sparing surgery has been performed to preserve renal function and quality of life, and prevent metastases. We evaluated a 3 cm. threshold for performing renal parenchymal sparing surgery in patients with von Hippel-Lindau disease and hereditary papillary renal cancer. MATERIALS AND METHODS Patients with von Hippel-Lindau disease or hereditary papillary renal cancer and renal cancer were identified by screening affected kindred and by kindred history. Patients with small tumors were followed with serial imaging studies until the largest renal tumor was 3 cm., when renal parenchymal sparing surgery was performed. Renal tumors greater than 3 cm. were resected without delay. Parenchymal sparing techniques were used when possible in each group. RESULTS The 3 cm. surgical threshold was evaluated in 52 patients with von Hippel-Lindau disease (group 1) at a median followup of 60 months (range 6 to 205). None of these patients had metastatic disease and none has required renal transplantation or dialysis. In 44 patients with von Hippel-Lindau disease (group 2) renal tumors larger than 3 cm. developed. Median followup from the initial radiological diagnosis of renal cancer in this group was 66.5 months (range 0 to 321). Patients in group 1 underwent parenchymal sparing surgery instead of nephrectomy more frequently than those in group 2 (46 of 48 operations or 96% versus 45 of 72 or 63%, Fishers exact test p <0.0001). In contrast to patients in group 1, metastatic renal cancer developed in 11 of the 44 in group 2 (25%) (Fishers exact test p <0.0001). A total of 23 patients with hereditary papillary renal cancer were also identified. Median followup in these cases was 44 months (range 0 to 237). Ten patients had tumors less than 3 cm. No patient with tumors less than 3 cm. and 2 of the 13 (15%) with larger tumors had metastases. CONCLUSIONS Using a 3 cm. renal tumor diameter as an indication for renal surgery no patient with renal cancer and von Hippel-Lindau disease or hereditary papillary renal cancer had metastatic disease regardless of the number of tumors. Using a lesion size of 3 cm. as a threshold for performing renal parenchymal sparing surgery may help to prevent metastatic disease, unnecessary renal damage due to frequent surgery and renal dialysis or transplantation.


The Journal of Urology | 1999

Management of hereditary pheochromocytoma in von Hippel-Lindau kindreds with partial adrenalectomy.

McClellan M. Walther; Harry R. Keiser; Peter L. Choyke; W. Rayford; J. Chris Lyne; W. Marston Linehan

PURPOSE In patients with von Hippel-Lindau disease multiple bilateral adrenal pheochromocytoma can develop, which has traditionally been treated with adrenalectomy. Partial adrenalectomy can preserve normal adrenal function and avoid the morbidity associated with medical adrenal replacement. We demonstrate whether adrenal function could be preserved by partial adrenalectomy in patients with von Hippel-Lindau disease. MATERIALS AND METHODS From 1995 to 1998, 13 consecutive von Hippel-Lindau disease patients with pheochromocytoma underwent 14 partial and 6 complete unilateral adrenalectomies. Function of residual normal adrenal and recurrence of adrenal pheochromocytoma were determined at followup. RESULTS Of the patients 2 had undergone unilateral adrenalectomy and 1 had undergone complete and partial adrenalectomy previously. Following surgery residual normal adrenal tissue consisted of 1 partial adrenal in 3 patients, bilateral partial adrenal in 5, partial and complete adrenal gland in 1, 1 complete adrenal gland in 3 and no adrenal tissue in 1. Three patients with residual adrenal tissue were placed on medical adrenal replacement until adrenocorticotropic hormone stimulation testing demonstrated adrenocortical function. In 2 patients 1 adrenal and 2 extra-adrenal new pheochromocytomas developed 11 and 152 months, respectively, after partial adrenalectomy. No morbidity related to pheochromocytoma was observed during followup. CONCLUSIONS Partial adrenalectomy can preserve adrenal function in patients with a hereditary form of pheochromocytoma.


The Journal of Urology | 2004

SERUM PROTEOMIC PROFILING CAN DISCRIMINATE PROSTATE CANCER FROM BENIGN PROSTATES IN MEN WITH TOTAL PROSTATE SPECIFIC ANTIGEN LEVELS BETWEEN 2.5 AND 15.0 NG/ML

David K. Ornstein; W. Rayford; Vincent A. Fusaro; Thomas P. Conrads; Sally Ross; Ben A. Hitt; Wesley W. Wiggins; Timothy D. Veenstra; Lance A. Liotta; Emanuel Petricoin


Nucleic Acids Research | 1991

A new polymorphic probe on chromosome 3p: λLIB13–49′ (D3S723)

F. Latif; Gladys M. Glenn; L. Geil; W. Rayford; J. Delisio; Berton Zbar; Michael I. Lerman


Nucleic Acids Research | 1991

A new polymorphic probe on chromosome 3p: lambda LIB46-100 (D3S641).

F. Latif; Gladys M. Glenn; W. Rayford; L. Geil; J. Delisio; K. Hampsch; Mary Lou Orcutt; Berton Zbar; Michael I. Lerman


Nucleic Acids Research | 1991

A new polymorphic probe on chromosome 3p:λLIB29-48(D3S624)

F. Latif; Gladys M. Glenn; W. Rayford; L. Geil; J. Delisio; K. Hampsch; Mary Lou Orcutt; Berton Zbar; Michael I. Lerman


Nucleic Acids Research | 1991

A new polymorphic probe on chromosome 3p: λLIB39–63 (D3S616)

F. Latif; Gladys M. Glenn; L. Geil; W. Rayford; J. Delisio; Berton Zbar; Michael I. Lerman


Nucleic Acids Research | 1991

A new polymorphic probe on chromosome 3p:λLIB46-95(D3S620)

F. Latif; Gladys M. Glenn; W. Rayford; L. Geil; J. Delisio; K. Hampsch; Mary Lou Orcutt; Berton Zbar; Michael I. Lerman


Nucleic Acids Research | 1990

A new polymorphic probe on chromosome 3p: λLIB45–86 (D3S633)

F. Latif; Gladys M. Glenn; L. Geil; W. Rayford; J. Delisio; Berton Zbar; Michael I. Lerman


The Journal of Urology | 1998

Renal Cancer: Preoperative Evaluation With Dual-Phase Three-Dimensional MR Angiography

Peter L. Choyke; McClellan M. Walther; Joseph R. Wagner; W. Rayford; John C. Lyne; William M. Linehan

Collaboration


Dive into the W. Rayford's collaboration.

Top Co-Authors

Avatar

Gladys M. Glenn

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Berton Zbar

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

L. Geil

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Michael I. Lerman

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

F. Latif

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Mary Lou Orcutt

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Farida Latif

University of Birmingham

View shared research outputs
Top Co-Authors

Avatar

Masahiro Yao

Yokohama City University

View shared research outputs
Top Co-Authors

Avatar

McClellan M. Walther

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Peter L. Choyke

National Institutes of Health

View shared research outputs
Researchain Logo
Decentralizing Knowledge